A woman inspecting a man's eye | Source: Pexels
Health

FDA Adds Vision Warning for Ozempic, Zepbound, and Other GLP-1 Medications: What Patients Should Know

By Claudine Varela Nov 20, 2026

A woman inspecting a man's eye | Source: Pexels

The FDA announced a rare risk of a condition that can cause sudden vision loss in one eye. Here are the symptoms to watch for, and why you shouldn’t stop your medication without talking to your doctor.

Advertisement

The U.S. Food and Drug Administration has issued a directive requiring all GLP-1 medications to include a new warning on their labels about the possible risk of a rare but serious eye condition.

On November 9, the FDA announced that information about the condition, called non-arteritic anterior ischemic optic neuropathy (NAION), should be added to the “warnings and precautions” section of the labels for all GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, which are widely used for type 2 diabetes and weight loss.

Advertisement

NAION is caused by reduced blood flow to the front part of the optic nerve, but the underlying cause is not completely understood. Symptoms can include sudden, painless vision loss in one eye, and in some cases, permanent loss of vision.

Some possible risk factors include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease, the FDA notes. Since many of these conditions are common among people taking GLP-1 drugs, the agency said reports of NAION were challenging to interpret on their own.

To find out how real the risk is, the FDA looked at clinical trials, animal studies, and data from real patients. In 126 clinical trials with more than 134,000 people, NAION was slightly more common among those taking GLP-1 drugs. For every 100,000 people taking the drugs for a year, there were about six cases of NAION, compared with about four cases among those taking a placebo or other diabetes drugs. However, the condition was still very rare, with only 15 cases in total.

A woman inspecting a man's eye | Source: Pexels

A woman inspecting a man's eye | Source: Pexels

Advertisement

In another FDA study of adults with type 2 diabetes, the results were mixed. People taking GLP-1 drugs didn’t have a higher risk than those on one type of diabetes medication, but they did have a higher risk than those on another type. Other published studies have also found a higher risk in people with type 2 diabetes who started GLP-1 drugs.

Based on these findings, the FDA concluded there is “a potential increased risk of rare NAION events” in people taking these medications. In 2025, the European Medicines Agency’s safety committee also estimated that up to 1 in 10,000 people taking semaglutide, the active ingredient in Ozempic and Wegovy, for at least a year may be affected by NAION.

Advertisement

The makers of these medicines have responded since the announcement, with Eli Lilly, maker of Mounjaro and Zepbound, saying the FDA’s communication “does not reference any findings specific to Lilly medicines,” though it is evaluating the update.

Meanwhile, Novo Nordisk, which makes Ozempic and Wegovy, says the data do not establish a cause-and-effect relationship, and it remains confident in its medicines’ benefits and risks

  • Sudden, painless vision loss in one eye, which may be noticed upon waking
  • Blurred vision, blind spots, or tunnel vision
  • Changes in how colors look
  • Blurry or hazy spots in the center of your vision

If you notice any of these symptoms, contact a healthcare professional right away. Should you be diagnosed with NAION, the FDA recommends talking with your healthcare professional about whether to continue your GLP-1 medication. And as with any medication, consult your doctor before stopping its use, since these drugs treat serious health conditions.

Advertisement

Advertisement